Free Newsletter
Transplant drug offers surprising boost for vaccines
A drug used to block immune cells from attacking transplanted organs also triggers the increased production of memory T-cells, and that could play a surprising role in boosting the effectiveness of cancer vaccines and other jabs.
Researchers at Emory University School of Medicine infected mice with a virus and then gave them the drug to determine how their bodies would respond. The mice treated with rapamycin not only had more memory T-cells than the control mice, they had better T-cells. And that gave the mice a much stronger set of defenses in the event the virus returned.
"We were completely surprised," says Rafi Ahmed. Now the researchers will try and determine how the drug can be dosed in a way that boosts T-cell production without suppressing the body's immune system, which would make it more vulnerable to attack.
- read the report from New Scientist
Related Articles:
Stem cell breakthrough in organ transplant
FDA stresses dangers of transplant meds
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




